Metastatic hidradenocarcinoma, case description and literature review.
Hidradenocarcinoma metastásico, descripción de un caso y revisión de la literatura.
Section
Clinic cases
How to Cite
Metastatic hidradenocarcinoma, case description and literature review.
Rev. colomb. hematol. oncol. [Internet]. 2017 Oct. 1 [cited 2024 Dec. 22];4(1):31-5. Disponible en: https://doi.org/10.51643/22562915.163
Dimensions
license
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Show authors biography
The hidradenocarcinoma is a rare neoplasm. There are no consensus guidelines for the local or systemic treatment of this disease. We describe a case of a 71-year-old male with a slow growing lesion that was treated with a non oncologic resection. The pathologic report informed a clear cell hidradenocarcinoma. After the diagnosis the chest scan documented metastatic disease. It was proposed a first line of chemotherapy using capecitabine, with progression after 5 cycles. The patient refused other chemotherapy lines. The hidradenocarcinoma usually presents as a long standing asymptomatic nodular lesion in the skin. Most of the diagnoses are made incidentally. The treatment includes surgery and nodal dissection. Half of the patients present local failure and eventually metastatic disease. The chemotherapy is used with a variety of drugs and results.
Article visits 180 | PDF visits 682
- Cardoso JC, Calonje E. Malignant sweat gland tumours: an update. Histopathology 2015;67(5):589-606.
- Gates O, Warren S, Warvi WN. Tumors of sweat glands. Am J Pathol 1943;19(4):591-631.
- Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol 2010;146(6):625-32.
- Bhullar JS, Varshney N, Mervak T, Mittal V, Silapaswan S. Hidradenocarcinoma: a sinister diagnosis of a suspected benign condition. Am Surg 2014;80(12):1271-2.
- Gauerke S, Driscoll JJ. Hidradenocarcinomas: a brief review and future directions. Arch Pathol Lab Med 2010;134(5):781-5.
- Massad LS, Bitterman P, Clarke-Pearson DL. Metastatic clear cell eccrine hidradenocarcinoma of the vulva: survival after primary surgical resection. Gynecol Oncol 1996;61(2):287-90.
- Messing MJ, Richardson MS, Smith MT, King L, Gallup DG. Metastatic clear-cell hidradenocarcinoma of the vulva. Gynecol Oncol 1993;48(2):264-8.
- Hasebe T, Mukai K, Ishihara K, Kaneko A, Shimosato Y. Sebaceous gland and sweat gland carcinomas of the skin. Clinicopathological study and significance of c-erbB-2 oncoprotein expression. Acta Pathol Jpn 1992;42(8):585-94.
- Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, Hoang MP. Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol 2010;32(6):586-92.
- Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors 2015;7(1):5719.
- Takata M, Hashimoto K, Mehregan P, Lee MW, Yamamoto A, Mohri S, et al. Genetic changes in sweat gland carcinomas. J Cutan Pathol 2000;27(1):30-5.
- Delgado R, Kraus D, Coit DG, Busam KJ. Sentinel lymph node analysis in patients with sweat gland carcinoma. Cancer 2003;97(9):2279-84.
- Elder DE, Elensitas R, Johnson BL, Murphy GF. Elders’s histopathology of the skin. Chapter 30 Tumors of the epidermal appendages. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
- Wang XX, Wang HY, Zheng JN, Sui JC. Primary cutaneous sweat gland carcinoma. J Cancer Res Ther 2014;10(2):390-2.
- Tlemcani K, Levine D, Smith RV, Brandwein-Gensler M, Staffenberg DA, Garg MK, et al. Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J Clin Oncol 2010;28(24):e412-4.
- Piedbois P, Breau JL, Morere JF, Israel L. Sweat gland carcinoma with bone and visceral metastases. Prolonged complete remission lasting 16 months as a result of chemotherapy. Cancer 1987;60(2):170-2.
- Chintamani, Sharma R, Badran R, Singhal V, Saxena S, Bansal A. Metastatic sweat gland adenocarcinoma: a clinico-pathological dilemma. World J Surg Oncol 2003;1(1):13.
- Lerner A, Beckford A, Ugent S, Goldberg L, Jalisi S, Demierre M. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment. Arch Dermatol 2011;147(8):998-9.
- Jouary T, Kaiafa A, Lipinski P, Vergier B, Lepreux S, Delaunay M, et al. Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol 2006;142(10):1366-7.
- Sridhar KS, Benedetto P, Otrakji CL, Charyulu KK. Response of eccrine adenocarcinoma to tamoxifen. Cancer 1989;64(2):366-70.
- Battistella M, Mateus C, Lassau N, Chami L, Boukoucha M, Du-villard P, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol 2010;24(2):199-203.
- Gallerani E, Ciriolo M, Rossini C, Cavalli F. Axillary apocrine carcinoma with brain metastases. J Clin Oncol 2007;25(35):5655-6.
- Nash JW, Barrett TL, Kies M, Ross MI, Sneige N, Diwan AH, et al. Metastatic hidradenocarcinoma with demonstration of Her-2/ neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol 2007;34(1):49-54.
- Chamberlain RS, Huber K, White JC, Travaglino-Parda R. Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. Am J Clin Oncol 1999;22(2):131-5.
- Kyrgias G, Kostopoulou E, Zafiriou E, Zygogianni A, Skarlatos J, Roussaki-Schulze AV, et al. Hidradenocarcinoma of the temporal area successfully treated with concomitant electrochemotherapy and radiotherapy. Head Neck Oncol 2013;5(2):14.
- Soni A, Bansal N, Kaushal V, Chauhan AK. Current management approach to hidradenocarcinoma: a comprehensive review of the literature. Ecancermedicalscience 2015;9:517.
About the journal
Information
Directories and indexers
Google Scholar profile
QR code
Keywords
Most read in the last 30 days
